✨ Free AI Report
GH Research PLC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research GH Research PLC
Company Research

GH Research PLC: Business Overview, Financials & Competitive Analysis

GH Research is a clinical-stage biopharmaceutical company focusing on developing novel mebufotenin therapies for treating treatment-resistant depression (TRD). The company's lead asset GH001 is an inhalable mebufoteni...

Analyst-debate audio for GH Research PLC

AskCyborg analysts argue the bull and bear cases for GH Research PLC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

GH Research is a focused biotech player with validated early-stage data in TRD pursuing novel psychedelic-derived therapeutics...

Read the full analyst-debate transcript →
Industry Biotechnology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest GH Research PLC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

GH Research PLC Overview

Pro stress-test →

GH Research is a clinical-stage biopharmaceutical company focusing on developing novel mebufotenin therapies for treating treatment-resistant depression (TRD). The company's lead asset GH001 is an inhalable mebufotenin candidate in Phase 2b clinical trials for TRD and Phase 2a trials for bipolar II disorder and postpartum depression.

Strategic Profile

Pro stress-test →

GH Research develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies targeting psychiatric disorders. The company is advancing a multi-indication pipeline with inhalable and intravenous formulations, positioning itself in the emerging psychedelic-derived therapeutics market for treatment-resistant conditions.

Competitive Landscape

Pro stress-test →

GH Research competes in the psychedelic-derived therapeutics space alongside other companies developing MDMA and psilocybin therapies for psychiatric indications. Direct competitors in TRD treatment include traditional antidepressant providers and emerging biotech firms developing esketamine analogs and novel mechanisms. GH Research's proprietary 5-MeO-DMT platform and inhalable/IV delivery approaches differentiate it in this nascent segment.

Industry Context

GH Research PLC operates in Biotechnology.

Key facts

Founded: 2018 · Headquarters: Dublin, Ireland · Employees: 73 · Market cap: $1.48B

What the analysts stress-tested

The top findings that survived the multi-agent debate for GH Research PLC.

  • Lead program GH001 met primary endpoints in Phase 2b TRD trial with -15.5 point placebo-adjusted MADRS reduction, demonstrating clinical efficacy
  • Company completed FDA IND hold resolution with no respiratory toxicity findings in non-rodent studies, clearing regulatory pathway forward
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Cantor Fitzgerald raised price target to $35 from $25 and initiated coverage at Overweight
  • February 2026Completed $150 million public offering to fund clinical development
  • +1 moreTrack every material event for GH Research PLC as it happens. Explore monitoring →
Get alerted when GH Research PLC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Esketamine (Spravato)FDA-approved intranasal ketamine for TRD→COMPASS Pathways ProgramPsilocybin therapy development for treatment-resistant depression→MDMA-Assisted TherapyMDMA-assisted psychotherapy for PTSD→

Compare GH Research PLC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

GH Research PLC operates in Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology research →
NEW · MCP server

Ask your AI assistant about GH Research PLC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare GH Research PLC and its top competitor on Cyborg Score”
“What did GH Research PLC do this quarter?”
“Is GH Research PLC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does GH Research PLC do?+
GH Research is a clinical-stage biopharmaceutical company focusing on developing novel mebufotenin therapies for treating treatment-resistant depression (TRD). The company's lead asset GH001 is an inhalable mebufoteni...
What is GH Research PLC's Cyborg Score?+
GH Research PLC has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are GH Research PLC's main competitors?+
Named competitors include Esketamine (Spravato), COMPASS Pathways Program, MDMA-Assisted Therapy. The full competitive landscape is in the AskCyborg report.
How can I get the full GH Research PLC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the GH Research PLC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track GH Research PLC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score